AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Phase I Trial Of Monoclonal Antibody Initiated.(Brief Article)
2001 AUG 8 - (NewsRx.com & NewsRx.net) --
XTL Biopharmaceuticals, Ltd. (XTL) announced the commencement of Phase I clinical studies with XTL-002, its human monoclonal antibody (MAb) being developed for the treatment of hepatitis C virus (HCV) infections.
The study, being conducted in Israel, is expected to enroll 15 patients and is designed to test safety, tolerability, and changes in viral levels in chronic hepatitis C patients. The trial is being conducted following U.S. Food and Drug Administration (FDA) and Israeli Ministry of Health approvals.
XTL-002 is a fully human high-affinity monoclonal antibody that was shown to reduce HCV levels in XTL's proprietary in vivo model. The company's HCV Trimera(XTL) model is being used in ...
- Enhancing alpha-helicity HIV peptide increases affinity for human monoclonal...
- Newspaper article from: Vaccine Weekly February 5, 2003 700+ words
...broadly neutralizing human monoclonal antibody 2F5. Efforts at eliciting...increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing...This article was prepared by Vaccine Weekly editors from staff and other...
- Radioiodinated monoclonal antibody effective against high-grade glioma.
- Newspaper article from: Vaccine Weekly February 26, 2003 700+ words
...Trials (Radioiodinated ([superscript]125I) monoclonal antibody 425 in the treatment of high grade glioma patients...and Immunotherapy. This article was prepared by Vaccine Weekly editors from staff and other reports.
- Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024.
- Press release article from: Business Wire September 30, 2009 700+ words
...catalogue. Reportlinker Adds Monoclonal Antibody Therapeutics 2009-2024 http...p0151198/Reportlinker-Adds-Monoclonal-Antibody-Therapeutics-2009-2024.html Monoclonal Antibody Therapeutics 2009-2024 - market...
- Monoclonal Antibody Therapeutics.
- Press release article from: M2 Presswire August 10, 2009 700+ words
...August 2009-Bharat Book Bureau: Monoclonal Antibody Therapeutics(C)1994-2009 M2...Bharatbook.com added a new report on "Monoclonal Antibody Therapeutics" this report examines...expansion into new therapeutic areas. Monoclonal Antibody Therapeutics Report ( http...
- Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and...
- Press release article from: PR Newswire November 5, 2009 700+ words
...is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape...reportlinker.com/p0158341/Monoclonal-Antibody-Therapies-2007-Co mpetitive...it barely surpassed 13 percent. Monoclonal antibody (MAbs) therapies have been posting...
- Research and Markets: Monoclonal Antibody Therapeutics: Current Market Dynamics...
- Press release article from: Business Wire July 16, 2004 700+ words
...Ireland -- The Global Market for Monoclonal Antibody (Mab) Therapeutics Reached a Total...has announced the addition of Monoclonal Antibody Therapeutics: Current Market Dynamics...offering. The global market for Monoclonal Antibody (Mab) Therapeutics reached a total...
- Research and Markets: Market for Monoclonal Antibody Therapeutics Has Been...
- Press release article from: PR Newswire May 18, 2005 700+ words
...has announced the addition of Monoclonal Antibody Therapeutics: Current Market Dynamics...RESEARCH ) The global market for Monoclonal Antibody (Mab) Therapeutics reached a total...from generics. The outlook for monoclonal antibody therapeutics is healthy. The ongoing...
- ImmunoCellular Therapeutics Granted Monoclonal Antibody Technology Patent.
- Press release article from: Business Wire April 29, 2009 700+ words
...patent relating to the company's monoclonal antibody therapeutics. Patent No. 7,498...IMUC, through its acquisition of monoclonal antibody-related technology from Molecular...antibody product candidate, is a monoclonal antibody targeting small cell lung cancer...
Source: HighBeam Research, Phase I Trial Of Monoclonal Antibody Initiated.(Brief Article)